Lower socioeconomic status: a risk factor for disseminated Lyme disease
Some individuals suffer from disseminated and chronic manifestations of Lyme disease, and some do not. In their article, “Risk factors for Lyme disease stage and manifestation using electronic health records,” Moon and colleagues look at risk factors for disseminated Lyme disease. 
Moon et al. explored the risk factors for disseminated Lyme disease using an electronic database from the Geisinger integrated health care system located in Pennsylvania. They based their data on both diagnostic and narrative text data.
One out of three of their disseminated Lyme disease cases were classified as disseminated cases. “Lyme arthritis was the most common manifestation (55%), followed by neurological manifestations (34%), carditis (6%), and secondary erythema migrans (7%),” wrote Moon and colleagues. Another 6% were classified as other manifestations.
Individuals with lower socioeconomic status (SES) were more likely to develop disseminated Lyme disease.
An individual was classified as having a lower SES if they used Medical Assistance at least half the time. In contrast, individuals using urgent care or having a regular relationship with a primary care doctor were less likely to develop disseminated Lyme disease.
Significance of findings
This study reinforces the role of socioeconomic status as reported in an earlier Geisinger study of Lyme disease patients. “Delayed diagnosis and treatment was attributed to appraisal delays (e.g., due to symptom misattribution, intermittent symptoms, atypical or no erythema migrans), behavioral delays in seeking care (e.g., due to inadequate health insurance) and misdiagnosis in urgent care or emergency settings,” wrote the authors.
Although the study did not describe the risk of delayed diagnosis and treatment in urgent care centers, the authors raised such concerns. “We speculate that misdiagnosis in urgent or emergency settings would be more likely with atypical erythema migrans or in cases without any rash, which we could not reliably assess in this study.”
The study has several limitations, including staging the disease and review of records.
The authors conclude, “Intervening on these factors could reduce the individual and health care burden of disseminated Lyme disease.”
Could race effect the diagnosis and treatment of Lyme disease?
Who is more likely to fail Lyme disease treatment?
6 reasons for delayed treatment of Lyme disease
- Moon KA, Pollak JS, Poulsen MN, Heaney CD, Hirsch AG, Schwartz BS. Risk factors for Lyme disease stage and manifestation using electronic health records. BMC Infect Dis. Dec 20 2021;21(1):1269. doi:10.1186/s12879-021-06959-y
When the average cost of treatment is out of pocket and minimal around USD 10 K in the USA, and many are spending five to ten times that, its no wonder its a poor man’s disease ? We really need patient rights respected and health care policy written by patients rights advocates and true scientists not insurance companies or corrupted medical associations working with pharmaceutical companies profiting from treating symptoms in untested or poorly tested and undiagnosed poor.